Enlivex Therapeutics Ltd.
Tel Aviv Stock Exchange ENLV.TA
Enlivex Therapeutics Ltd. Dividend Yield on January 14, 2025: 0.00%
Enlivex Therapeutics Ltd. Dividend Yield is 0.00% on January 14, 2025, a 0.00% change year over year. Dividend yield measures the dividend per share relative to stock's price value; higher yield suggests higher dividend return.
-
Enlivex Therapeutics Ltd. 52-week high Dividend Yield is 0.00% on January 14, 2025, which is 0.00% below the current Dividend Yield.
-
Enlivex Therapeutics Ltd. 52-week low Dividend Yield is 0.00% on January 14, 2025, which is 0.00% below the current Dividend Yield.
-
Enlivex Therapeutics Ltd. average Dividend Yield for the last 52 weeks is 0.00%.
Key data
| Date | Dividend Yield | Free Cash Flow Yield | Earnings Yield | Enterprise Value (EV) |
|---|
Market news
Loading...
Tel Aviv Stock Exchange: ENLV.TA
| CEO | Dr. Oren Hershkovitz Ph.D. |
| IPO Date | July 22, 2019 |
| Location | Israel |
| Headquarters | 14 Einstein Street |
| Employees | 77 |
| Sector | Health Care |
| Industries | |
Description
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. The company has a collaboration agreement with BeiGene to evaluate the safety and efficacy of Allocetra in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor for the treatment of patients with advanced-stage solid tumors. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.
Key trends
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email